Journal of Research and Development
Open Access

Oliver Steinbach

Biography

Oliver Steinbach PhD joined the Clincial Research Board of Philips Healthcare on August 1, 2011 and is located in Cleveland, Ohio, responsible for developing and managing the clinical relationships in the mid-west of the USA and Canada as well as selected sites in Europe. In this role, he is coordinating preclincial and clinical research and trial activities, and is also responsible for the the Research Physician Fellowship program.

Before Oliver Steinbach was leading the department Bio-Molecular Engineering since 2006 which is focusing on molecular diagnostics and imaging applications as well as image-guided therapy and drug delivery to generate new business opportunities by exploring combinations of various imaging modalities and novel imaging contrast agents for diagnostic and therapeutic applications.

Previously Oliver Steinbach worked in various R&D positions at ALTANA Pharma AG (1999-2006). Major assignments were Head of Functional Genomics, Head Technology Management and Director of Functional Screening, where he was involved in the built up and growth of the Functional Genomics Departments and the ALTANA Research Institute in Waltham, MA, USA and ALTANA Pharma AG headsquarters in Konstanz Germany.

Specializing amongst other applications on genomics, proteomics, RNAi technology and high content imaging with underlying automation technology and bioinformatics he managed the discovery and validation of novel pharmaceutical targets used in the treatment of inflammation, gastroenterology, and oncology.

Oliver Steinbach received his Ph. D. degree in biochemistry from the University of Tuebingen, Germany in 1998, and was awarded with the Otto-Hahn-Medal of the Max-Planck Society.

Research Interest

New technologies and therapeutic/diagnostic concepts
• Business development (life science and pharma)
• Methods in biochemistry, genomics and proteomics, functional genomics, molecular imaging
• Cell signaling and transcriptional regulation, epigenesis,
• Gene inactivation (especially dominant-negative mutants, antisense RNA, ribozyme antisense-oligonucleotides, RNAi).
• Bioinformatics,
• Oncology (tumor apoptosis, chemosensitization, kinases and HDAC)
• Inflammation (T-cell biology, asthma, COPD, osteoarthritis, rheumatoid arthritis).
• Target identification and validation, assay development and high-throughput drug screening
• High-content screening and preclinical imaging technologies, confocal, optical, PET, SPECT, CT, MRI, image processing and analysis; diagnostic devices and assays